GLUE

MONTE ROSA THERAPEUTICS, INC.

GLUE · CIK 1826457 · Annual (10-K) · Last 4 years

Financial Trends

Revenue
20212024
Net Income−$73M
20212024
Operating CF$42M
20212024
Free Cash Flow$38M
20212024

Income Statement

MetricFY 2024FY 2023FY 2022FY 2021
Revenue
Cost of Revenue
Gross Profit
R&D Expense$0.1B$0.1B$0.1B$0.1B
SG&A Expense
Operating Income$-0.1B$-0.1B$-0.1B$-0.1B
Net Income$-0.1B$-0.1B$-0.1B$-0.1B
EPS (Basic)
EPS (Diluted)

Balance Sheet

MetricFY 2024FY 2023FY 2022FY 2021
Total Assets$0.4B$0.3B$0.3B$0.4B
Current Assets$0.4B$0.2B$0.3B$0.3B
Cash & Equivalents$0.2B$0.1B$0.1B$0.3B
Total Liabilities$0.2B$0.1B$0.1B$0.0B
Current Liabilities$0.2B$0.0B$0.0B$0.0B
Stockholders' Equity$0.2B$0.2B$0.3B$0.3B

Cash Flow Statement

MetricFY 2024FY 2023FY 2022FY 2021
Operating Cash Flow$0.0B$-0.0B$-0.1B$-0.1B
Investing Cash Flow$-0.0B$0.1B$-0.2B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.1B$0.0B$0.0B$0.4B